Where does Sionna Therapeutics, Inc. Common Stock's cash flow data come from?

Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$85.57M-29.0%	-$75.27M-22.0%	-$70.68M—	-$75.84M—	-$66.32M—
Depreciation and amortization	$506K-30.3%	$511K-30.3%	$526K—	$626K—	$726K—
Stock-based compensation	$16.53M+221%	$12.07M+225%	$9.3M—	$7.02M—	$5.16M—
Change in accounts payable	-$2.76M—	-$417K—	$1.38M—	-$950K—	——
Change in accrued liabilities	——	——	——	——	-$618K—
Change in other assets	$960K-53.8%	$2.26M-18.2%	$1.3M—	$2.01M—	$2.08M—
Non-cash operating lease expense	$1.96M-0.1%	$1.96M0.0%	$1.96M—	$1.96M—	$1.96M—
Change in operating lease liabilities	-$2.14M-2.9%	-$2.13M-12.2%	-$2.11M—	-$2.1M—	-$2.08M—
Net cash from operating activities	-$71.85M-28.5%	-$66.3M-25.6%	-$61.45M—	-$63.91M—	-$55.9M—
Capital expenditures	$291K+158%	$377K+1,296%	$200K—	$113K—	$113K—
Purchases of investments	$178.76M-22.5%	$325.03M+77.8%	$289.35M—	$258.3M—	$230.51M—
Proceeds from maturities/sales of investments	$226.31M+162%	$206.65M+269%	$163.44M—	$119.61M—	$86.44M—
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of common stock	$5.85M+4,203%	$3.64M+2,481%	$2.01M—	$104K—	$136K—
Net cash from financing activities	$5.53M—	$206.02M—	——	——	——
Net increase (decrease) in cash	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$2.56M-28.8%	$3.05M+1.7%	$3.49M—	$3.65M—	$3.59M—
Depreciation	$506K-30.3%	$511K-30.3%	$526K—	$626K—	$726K—
Operating lease liabilities	-$2.14M-2.9%	-$2.13M-12.2%	-$2.11M—	-$2.1M—	-$2.08M—
Increase (Decrease) in Prepaid Expense and Other Assets	$960K-53.8%	$2.26M-18.2%	$1.3M—	$2.01M—	$2.08M—
Operating lease right-of-use asset amortization	$1.96M-0.1%	$1.96M0.0%	$1.96M—	$1.96M—	$1.96M—
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$226.31M+162%	$206.65M+269%	$163.44M—	$119.61M—	$86.44M—
Payments Of Stock Issuance Costs	——	——	——	——	——
Net proceeds from sales of subsidiary shares	——	——	——	——	$202.39M—
Exchange Offer (Note 12)	——	——	——	——	$330.37M—
Increase Decrease In Operating Lease Liability	-$2.14M-2.9%	-$2.13M-12.2%	-$2.11M—	-$2.1M—	-$2.08M—
Deferred offering costs in accrued expenses and accounts payable	——	——	——	——	——
Offering costs transferred to additional paid in capital	——	——	——	——	$4.27M—
Proceeds receivable from stock option exercises	——	——	——	——	——
Free cash flow	-$72.14M-28.8%	-$66.67M-26.2%	-$61.65M—	-$64.02M—	-$56.01M—
Free cash flow	-$72.14M-28.8%	-$66.67M-26.2%	-$61.65M—	-$64.02M—	-$56.01M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Sionna Therapeutics, Inc. Common Stock's cash flow data come from?: Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.